FDA awards new grants to support developing & assessing complex generic drugs
Certara’s Simcyp physiologically-based pharmacokinetic (PBPK) Simulator is being used to verify and expand biosimulation models for assessing virtual bioequivalence (VBE) of complex generic drugs PRINCETON, N.J.— February 7, 2023. Certara (Nasdaq: CERT), a global leader in biosimulation, today announced the Company has been awarded work with the University of Florida and the University of Rhode … Continued
https://www.certara.com/announcement/fda-awards-new-grants-to-support-developing-assessing-complex-generic-drugs/